VALN - Valneva Vaccines Price/Earnings to Growth Ratio

Valneva SE is scaling profits by leveraging its patent portfolio alongside low dose-production costs. Plant capacities are operating with high efficiency. The shift in the PEG ratio reflects the market's valuation of growth rates, with the current mark standing at 0.00. Valneva SE maintains its status as a reputable European developer, offering reliable solutions to combat infectious threats and travelers' diseases.

Valneva Corp (VALN): Price/Earnings to Growth Ratio from 07/04/2022 to 11/10/2026

Metric breakdowns and analytics for Valneva SE (VALN)

- share price and consensus valuation forecast:

Price Performance Chart Valneva Corp|VALN - Consensus Target

- market capitalization statistics:

Market Value Valneva Pharma|VALN - Enterprise Value

- issuer book value statistics:

Net Assets per Share Valneva|VALN - Company Book Value|Market Value to Book Value valneva.com|VALN - Cumulative Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

VALN - Company Net Income|Net Profit Forecast Valneva SE|VALN - P/E Multiple|Projected Price to Earnings Ratio Valneva Vaccines|VALN - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Valneva Pharma|VALN - Operating profit EBITDA|Net earnings per share (EPS TTM) Valneva|VALN - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months valneva.com|VALN - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Valneva SE

Summary company analytics:Valneva Corp VALN

Investors are verifying the issuer's reliability by comparing the market value of earnings with their growth dynamics. An analysis of the growth-weighted P/E allows for the determination of Valneva SE (VALN) undervaluation if the ratio is below one, which is critical for a company expanding its presence in an unsaturated tropical infection vaccine market through new regulatory approvals and government contracts.

Competing companies